Skip to main content
Livermore
Livermore
ZHEN

Alphabet Inc.

SEC CIK
0001652044
Latest filing
Aug 6, 2026

The latest 13F from Alphabet Inc. covers Q2 2026 (filed Aug 6, 2026): 28 long positions worth $99.1B. The top 10 holdings make up 99.5% of the portfolio, and the largest is Space Exploration Technologies Corp (SPCX) at 95.0%. Livermore has 22 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
3
Est. +$94.4B
Added
0
Reduced
4
Est. −$77.9M
Sold out
1
Est. −$631.8K

Top 5 holdings

Share of this quarter's portfolio value

  1. SPCXSpace Exploration Technologies Corp
    95.0%$94.2BHistory
  2. PLPlanet Labs PBC
    1.2%$1.17BHistory
  3. ASTSAST SpaceMobile, Inc.
    0.8%$794.7MHistory
  4. CMECME Group Inc.
    0.8%$769.4MHistory
  5. ARMArm Holdings PLC
    0.7%$695.2MHistory

Biggest buys

New and added positions, by estimated amount bought

  1. SPCXSpace Exploration Technologies Corp
    +$94.2BNewHistory
  2. PBLSParabilis Medicines, Inc.
    +$134.6MNewHistory
  3. FRVOFervo Energy Co
    +$51.5MNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. SPCXSpace Exploration Technologies Corp
    +95.05 pp0.0% → 95.0%History
  2. PBLSParabilis Medicines, Inc.
    +0.14 pp0.0% → 0.1%History
  3. FRVOFervo Energy Co
    +0.05 pp0.0% → 0.1%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. RVMDRevolution Medicines, Inc.
    −$64.8MReducedHistory
  2. GLUEMonte Rosa Therapeutics, Inc.
    −$7.55MReducedHistory
  3. RLAYRelay Therapeutics, Inc.
    −$2.88MReducedHistory
  4. LIFEEthos Technologies Inc.
    −$2.68MReducedHistory
  5. TNYATenaya Therapeutics, Inc.
    −$631.8KSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. RVMDRevolution Medicines, Inc.
    −7.42 pp8.0% → 0.6%History
  2. LIFEEthos Technologies Inc.
    −0.98 pp1.0% → 0.1%History
  3. RLAYRelay Therapeutics, Inc.
    −0.36 pp0.4% → <0.1%History
  4. GLUEMonte Rosa Therapeutics, Inc.
    −0.27 pp0.3% → <0.1%History
  5. TNYATenaya Therapeutics, Inc.
    −0.02 pp<0.1% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$99.1B
+$95.1B (+2,367.4%) vs. prior quarter
Positions
28
+2 vs. prior quarter
Top 10 concentration
99.5%
Top 10 as share of value
Turnover
0.2%
Q2 2026, one quarter
Average holding period
1.5 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $99.1B (Q2 2026)

Q1 2021: $2.48BQ2 2021: $4.91BQ3 2021: $4.22BQ4 2021: $4.14BQ1 2022: $3.08BQ2 2022: $1.84BQ3 2022: $1.96BQ4 2022: $1.72BQ1 2023: $1.80BQ2 2023: $1.86BQ3 2023: $1.56BQ4 2023: $2.16BQ1 2024: $2.51BQ2 2024: $1.97BQ3 2024: $1.84BQ4 2024: $1.72BQ1 2025: $1.58BQ2 2025: $2.14BQ3 2025: $2.41BQ4 2025: $2.58BQ1 2026: $4.02BQ2 2026: $99.1B
Q1 2021Q2 2026
13F filings of Alphabet Inc. by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 6, 202628$99.1BSPCXPLASTSvs. Q1 2026SEC
Q1 2026May 8, 202626$4.02BCMEPLASTSvs. Q4 2025SEC
Q4 2025Feb 13, 202629$2.58BASTSPLRVMDvs. Q3 2025SEC
Q3 2025Nov 7, 202537$2.41BASTSPLARMvs. Q2 2025SEC
Q2 2025Aug 1, 202536$2.14BASTSARMFRSHvs. Q1 2025SEC
Q1 2025May 2, 202540$1.58BFRSHARMASTSvs. Q4 2024SEC
Q4 2024Feb 7, 202540$1.72BGTLBFRSHARMvs. Q3 2024SEC
Q3 2024Nov 8, 202442$1.84BGTLBARMRVMDvs. Q2 2024SEC
Q2 2024Aug 2, 202442$1.97BGTLBARMRVMDvs. Q1 2024SEC
Q1 2024May 3, 202443$2.51BGTLBCRWDDXCMvs. Q4 2023SEC
Q4 2023Feb 9, 202444$2.16BDXCMCRWDPATHvs. Q3 2023SEC
Q3 2023Nov 13, 202345$1.56BPATHCRWDVERVvs. Q2 2023SEC
Q2 2023Aug 4, 202347$1.86BPATHVERVOSCRvs. Q1 2023SEC
Q1 2023May 11, 202349$1.80BPATHPRMECRWDvs. Q4 2022SEC
Q4 2022Feb 14, 202351$1.72BPRMEVERVPATHvs. Q3 2022SEC
Q3 2022Nov 15, 202249$1.96BVERVEQRXPATHvs. Q2 2022SEC
Q2 2022Nov 15, 202255$1.84BDXCMPATHEQRXvs. Q1 2022SEC
Q1 2022Nov 15, 202260$3.08BDXCMPATHIONQvs. Q4 2021SEC
Q4 2021Nov 15, 202258$4.14BPATHVERVDXCMvs. Q3 2021SEC
Q3 2021Nov 15, 202243$4.22BPATHVERVDXCMvs. Q2 2021SEC
Q2 2021Nov 15, 202236$4.91BPATHVERVOSCRvs. Q1 2021SEC
Q1 2021Nov 15, 202232$2.48BOSCRLYFTDXCM–SEC

13D and 13G filings

Companies where Alphabet Inc. reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

Alphabet Inc. does not currently report owning 5% or more of any company.

Latest filings

11 filings on file made by Alphabet Inc. or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by Alphabet Inc.
CompanyFiled (ET)FilerFormStakeChangeEvent dateFiling
WULFTerawulf Inc.Sep 25, 20264:15 PM ETGoogle LLCand 2 others13G7.60%41.0M sharesNewSep 11, 2026SEC
SPCXSpace Exploration Technologies CorpAug 14, 20264:15 PM ETGoogle LLCand 2 others13G7.20%551.2M sharesNewJun 30, 2026SEC
LIFEEthos Technologies Inc.Aug 7, 20264:11 PM ETGV 2019, L.P.and 8 others13G/A11.70%3.62M shares−0.50 ppfrom 12.20%Jun 30, 2026SEC
LIFEEthos Technologies Inc.May 1, 20264:44 PM ETGV 2019, L.P.and 8 others13G12.20%3.77M sharesNewMar 31, 2026SEC
MAZEMaze Therapeutics, Inc.Feb 6, 20264:32 PM ETGV 2019, L.P.and 8 others13G/A2.90%1.39M shares−2.60 ppfrom 5.50%Below 5%Dec 31, 2025SEC
PRMEPrime Medicine, Inc.Nov 12, 20254:30 PM ETGV 2019, L.P.and 11 others13G/A12.30%16.6M shares–Sep 30, 2025SEC
VERVVerve Therapeutics, Inc.Jul 28, 20255:21 PM ETGV 2017, L.P.and 12 others13G/A0.00%0 shares–Below 5%Jul 25, 2025SEC
STCBStarco Brands, Inc.May 19, 20257:08 PM ETGV 2016, L.P.and 5 others13G/A18.80%147.5M shares+3.40 ppfrom 15.40%May 15, 2025SEC
MAZEMaze Therapeutics, Inc.May 9, 20254:15 PM ETGV 2019, L.P.and 8 others13G5.50%2.41M sharesNewMar 31, 2025SEC
STCBStarco Brands, Inc.Feb 13, 20254:15 PM ETGV 2016, L.P.and 5 others13G/A15.40%99.5M shares–Dec 31, 2024SEC
GTLBGitlab Inc.Feb 13, 20254:15 PM ETGV 2017, L.P.and 8 others13G/A4.30%6.09M shares–Below 5%Dec 31, 2024SEC